Why disciplined small molecule lead optimization outperforms fast iteration
In small molecule lead optimization, speed is often mistaken for progress: design-make-test-analyze (DMTA) cycles progress, compound counts rise, and potency improves. But many programs that move fastest on paper move slowest in reality.
When medicinal chemistry runs ahead of understanding, structure-activity relationship (SAR) becomes descriptive rather than predictive. People see trends come and go, activity cliffs emerge without explanation, and ADME signals fluctuate. The data accumulate, but confidence does not.
Effective lead optimization strategies are built around a narrowing of options, since each program starts with multiple possible directions but limited certainty about which one will succeed. The job of lead optimization is to reduce that uncertainty until the risks are well enough understood to progress.
More compounds do not equal more knowledge
In early optimization, it’s tempting to explore multiple vectors at once, like new substituents, polarity shifts, ring edits, and lipophilicity jumps. But if potency changes while multiple parameters are being assessed simultaneously, the driver can remain unclear. Teams will typically compensate by synthesizing more analogs, hoping patterns will stabilise. Yet in our experience, they rarely do.
Clear SAR depends on controlled variation – one-variable-at-a-time changes against a stable background – and when design tightens, interpretation sharpens. Perhaps the lipophilicity gradient tracks with potency or it doesn’t. Or an increase in polarity either affects permeability or it doesn’t. Over time, causality becomes visible.
This can feel slower as fewer compounds are made. But each compound answers a defined question and predictive SAR emerges earlier, which makes subsequent cycles faster and more rational. Even when SAR becomes interpretable, another trap appears: potency alone can mislead optimization.
Potency without causality creates drift
Potency is often the first optimization milestone, where nanomolar activity feels like progress. But potency can be driven by lipophilicity, aggregation, or non-specific binding. Without interrogation, these drivers remain hidden.
Later, if solubility collapses, clearance increases, or safety margins narrow, then months of chemistry must be unwound, which is associated with additional cost and delays. Slowing down after early potency gains to test mechanism prevents this drift. Does activity scale with cLogP? Does it persist in serum? Does improved potency correlate with exposure or simply with increased hydrophobicity?
Answering these questions early stabilizes direction and we see lead optimization becomes a controlled balancing exercise rather than a series of rescues.
ADME data should clarify, not fragment
Early ADME signals often trigger rapid pivots: high clearance, moderate solubility, variable permeability. This triggers multiple rescue strategies to launch in parallel… and the chemistry you spent so long piecing together, fragments. But not all ADME findings deserve immediate correction. While some reflect modifiable properties, others reveal scaffold-level constraints – and reacting without interpretation increases noise.
Slowing chemistry here means classifying the signal and determining which mechanism is truly driving the ADME findings. Is clearance metabolic or instability-driven? Is permeability polarity-limited or efflux-mediated? Once the mechanism is understood, fewer compounds are required to address it. The result is the program direction stabilizes and cycles shorten.
The real bottleneck is decision clarity
Most delays in small molecule lead optimization arise from slow decision-making – uncertainty about what the data actually means – rather than synthesis timelines. Fast chemistry increases that burden when interpretation lags and disciplined, hypothesis-led cycles reduce it. Each iteration is designed to collapse a specific uncertainty. When results arrive, the next decision is obvious: continue, pivot, or stop.
Stopping earlier is often the fastest outcome.
It’s easy to think that slowing chemistry means reducing intensity, when in reality, it means narrowing focus. With fewer simultaneous variables we have clearer experimental intent, which allows for explicit decision criteria before synthesis begins.
At Symeres, we treat lead optimization strategies as decision frameworks – that means moving away from the relentless demand for higher and higher throughput and compound-generation engines. Before the next cycle, we ask: what uncertainty is limiting progression, and what minimal set of compounds would resolve it?
When uncertainty declines faster than compound count increases, programs speed up. In small molecule lead optimization, narrowing options – not increasing speed – determines how quickly you reach a viable candidate.
About the author
Melloney Dröge is Managing Director, Drug Discovery at Symeres, where she leads the global Discovery organization and oversees the Groningen and Nijmegen sites. A pharmacist by training (PharmD, University of Groningen), she earned a PhD in Pharmaceutical Biology on biocatalysis under Prof. W.J. Quax. After a brief period as Assistant Professor in Molecular Pharmacology, she spent over 22 years in the CRO/CDMO sector in roles including Study Director, Technical Director, Head of Sales, and Managing Director. She has authored multiple peer-reviewed publications and focuses on building high-performing teams that deliver scientific excellence and sustainable business growth.
Resources we think you'll love
Blog
When a clean PK profile is actually a warning sign
A clean pharmacokinetics profile is often seen as a green light. But in practice, overly tidy PK data can hide analytical artefacts, non-linear behaviour, or poorly understood clearance mechanisms that surface later at significant cost.
Blog
CDMO red flags you can’t ignore: Communication breakdowns
Communication breakdowns rarely start as major problems, but small gaps in coordination can quietly slow progress and erode trust in CDMO partnerships.
Blog
CDMO red flags you can’t ignore: Capacity constraints and resource stretch
Part 4: When “Too Busy” Becomes a Business Risk Even the most capable CDMO cannot deliver high-quality work if it is stretched too thin. As demand for outsourcing continues to rise across the life sciences sector, many CDMOs are operating near or beyond capacity. For pharma and biotech companies, this creates a silent but serious […]
Blog
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Part 3: Could Regulatory Misalignment Be Delaying Your Submission? A CDMO can have the best scientists, excellent facilities, and strong technical execution, yet still fall short when it comes to regulatory alignment. This disconnect between scientific performance and regulatory readiness is one of the most damaging red flags in drug development as it could delay […]
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Selecting the right CDMO is one of the most important choices a biotech or pharma team will make. The right partner helps you move efficiently toward IND or IMPD, safeguard quality, and anticipate regulatory needs before they become roadblocks. The wrong one can mean delays, rising costs, and lost momentum. At Exemplify BioPharma, a Symeres company, […]
Blog
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Part 2: Why “Scale-Up” Isn’t Just a Bigger Batch Transitioning a process from discovery scale to GMP manufacturing is almost never straightforward. What runs smoothly at 100 milligrams in the lab can behave very differently at the kilogram scale. Yet too many programs falter because the complexity of this transition is underestimated or treated as […]
Blog
O.N.E Symeres: A practical approach to real-world drug development
No drug development program runs perfectly. Chemistry misbehaves, funding shifts, and timelines tighten. But what defines a reliable partner is how they respond. O.N.E Symeres is the framework we use to keep projects moving through uncertainty: openness, nimbleness, and expertise.
Blog
CDMO red flags you can’t ignore: Undefined or shifting project scope
Part 1: Is an Undefined Scope Putting Your Project at Risk? Selecting the right CDMO is one of the most important decisions in drug development. Yet even experienced biotechs and pharma companies can find themselves trapped in projects where the initial excitement gives way to frustration, and one of the most common culprits is a […]
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
By combining automation, data-driven design, and deep synthetic expertise, Symeres is redefining how chemists generate and optimize compound libraries, bringing speed, scalability, and creativity to modern drug discovery.
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
From the classical and Dutch resolution methods to preferential crystallization and deracemization, learn the best ways to obtain your desired purity!
Whitepaper
IND & IMPD enabling developability roadmap
Drug discovery and development is a complex and iterative process that involves the identification, design, development, testing, and approval of new pharmaceutical drugs for use in patients. It encompasses a series of scientific, regulatory, and commercial activities aimed at discovering and bringing safe and effective medicines to the market. A key milestone in this process […]
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Unnatural amino acids enable groundbreaking advancements in drug discovery, biomaterials, and peptide design by introducing novel chemical functionalities that enhance stability, specificity, and bioactivity. This whitepaper highlights Symeres’ expertise in synthesizing unnatural amino acids, including side-chain modifications, N-functionalization, and cyclic variants, for applications in pharmaceuticals, diagnostics, and materials science. Utilizing advanced techniques like biocatalysis and […]
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Our experience in overcoming scaleup challenges and harnessing the benefits of non-noble-metal catalysis makes Symeres the CRO of choice for challenging steps, such as the Ullmann reaction.
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
A comprehensive overview of nitrosamine risk assessment, including potential formation, scavenging, and analysis, is described here.
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Here at Symeres, we have our new ‘Solid-State Center of Excellence’, and in this whitepaper we describe how we utilize our expertise and novel innovation to further our solid-state capabilities.
Whitepaper
Stable isotope-labeled compounds
Discover how Symeres applies advanced synthetic chemistry and ADME expertise to design, produce, and study stable isotope-labelled compounds that enhance precision in drug development.
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Learn how Symeres combines advanced chemistry platforms and deep discovery expertise to design and expand the SymeGold library, driving more efficient high-throughput screening and smarter hit identification.
Interviews
Insights into drug discovery and development 2025
Here we interview our Director of Medicinal Chemistry, Anita Wegert, for her insights into drug discovery and development for 2025. This interview was conducted an interviewer from the Drug Discovery and Development Europe event and we were able to share our expertise. Curious how our insights can help your next project?
Interviews
Interview with the computer-aided drug design (CADD) department
Our Computer Aided Drug Design department supports our clients' drug discovery projects with some of the best (predictive) software.
Interviews
Meet the Organix Director, Mario Gonzalez
We are pleased to share a conversation with Dr. Mario Gonzalez, a Director at Organix, as he reflects on his journey from Argentina to Massachusetts and provides valuable career insights in celebration of his 30 years with the company.
Interviews
Interview with the new Managing Director of Symeres Groningen
On October 2, Dr Melloney Dröge started in her new role as Managing Director for the Groningen site.
Interviews
An interview with Yadan Chen and Paul O’Shea
We are pleased to introduce the founders of Symeres’ daughter company Exemplify in New Jersey: Yadan Chen, CEO, and Paul O’Shea, Chief Scientific Officer. Who are they? What do they stand for? And how does Exemplify fit with Symeres?
Interviews
An interview with Anu Mahadevan and Paul Blundell
We proudly introduce the founders of Symeres’ daughter company Organix in Boston: Anu Mahadevan, CEO, and Paul Blundell, President at Organix. Who are they? What do they stand for? And how does Organix fit with Symeres?
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Organix, a Symeres company, developed scale up conditions of the synthesis of 25-hydroxy cholesterol 3-monosulfate (sodium salt) from cholesterol. After the protection of the hydroxy group (acetate) and double bond (debromination), the hydroxy group in position 25 was introduced using oxone and trifluoromethylethylketone. Then the 3-hydroxy group and double bond were deprotected, and the resulting […]
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Despite a good part of ADME research in drug discovery and preclinical development can be performed using various in silico or in vitro systems, eventually it becomes necessary to evaluate the pharmacokinetic (PK) profile in animals to elucidate in vivo DMPK properties of the drug candidates.
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Medicinal chemistry is the art of rapidly evolving initial hits to clinical candidates via smart, information driven multiparametric optimization.
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
The webinar by Dr. Edwin Aret of Symeres focuses on advanced strategies for selecting and controlling solid forms of pharmaceutical compounds through crystallization techniques.
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
The webinar by Dr. Martin Strack provides an in-depth exploration of the strategies and considerations involved in developing scalable synthetic routes for Active Pharmaceutical Ingredients (APIs)
Webinar | On-demand
Solid-state chemistry part I: Introduction
This webinar, presented by solid-state expert Edwin Aret, offers an insightful introduction to the field of solid-state chemistry.
Speak with our experts
Let’s discuss how Symeres can support the discovery and development of your next breakthrough